Home » Newsletters » BioWorld Science

BioWorld Science

July 25, 2002

View Archived Issues

Plexus Vaccine and GlaxoSmithKline sign vaccine research agreement

Safety review of BLP25 phase IIb trial

Organogenesis negotiates return of Apligraf rights from Novartis

MPEP, a selective mglu5 antagonist: potential in drug dependence, parkinsonism and anxiety

Maintenance of CD4 T-cell levels reported in HIV patients treated with Remune

VE-cadherin antibody for cancer and other disorders associated with angiogenesis

Chimeric form of anti-CD40 MAb prepared by Tanox and proven safe and effective in animals

Renal cytoprotective effects demonstrated for calpain inhibitors

Potassium channel opener selective for pancreatic beta-cell channels discovered at Novo Nordisk

TAK-013 undergoes early clinical trials for endometriosis, uterine fibroids

Sanofi-Synthelabo presents novel beta3-adrenoceptor agonists for obesity, diabetes, etc.

Collagen-derived agent for dry eye syndrome licensed by Santen

Novel 5-HT2C agonists jointly reported by Roche and Vernalis

NeuroSearch claims quinuclidines with nicotinic/monoamine transporter-modulating activity

Vasopressin antagonists identified at Yamanouchi

Karo Bio to outlicense KB-002611

New FTase inhibitors in early development at Schering-Plough

Ajinomoto pipeline includes new lactams for lowering blood glucose

ViaCell to study stem cells in the treatment of diabetes

Kyorin researchers identify new PPARalpha agonists with potential in lipoprotein disorders

Serono to develop anastrozole for female infertility

Ampligen promising in salvage therapy and HAART/STI regimens

GeneFormatics and De Novo form MMP drug discovery collaboration

Phase III trial of Chrysalin for fracture repair given go-ahead

Oxigene updates second-quarter progress of key vascular targeting agents

Approvable letter received for vardenafil

Eligard 22.5 mg approved for advanced prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...